EMDB/PDB/SASBDBから引用されている文献のデータベース

キーワード
構造解析手法	All X線回折 NMR 電子顕微鏡小角散乱中性子線回折線維回折粉末回折赤外分光 EPR FRET 理論モデルハイブリッド
著者・登録者
ジャーナル
IF	>30 >20 >10 >5 all

タイトル	Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain.
ジャーナル・号・ページ	Cell Rep, Vol. 37, Issue 2, Page 109822, Year 2021
掲載日	2021年10月12日
著者	Adam K Wheatley / Phillip Pymm / Robyn Esterbauer / Melanie H Dietrich / Wen Shi Lee / Damien Drew / Hannah G Kelly / Li-Jin Chan / Francesca L Mordant / Katrina A Black / Amy Adair / Hyon-Xhi Tan / Jennifer A Juno / Kathleen M Wragg / Thakshila Amarasena / Ester Lopez / Kevin J Selva / Ebene R Haycroft / James P Cooney / Hariprasad Venugopal / Li Lynn Tan / Matthew T O Neill / Cody C Allison / Deborah Cromer / Miles P Davenport / Richard A Bowen / Amy W Chung / Marc Pellegrini / Mark T Liddament / Alisa Glukhova / Kanta Subbarao / Stephen J Kent / Wai-Hong Tham /
PubMed 要旨	Potent neutralizing monoclonal antibodies are one of the few agents currently available to treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the viral spike ...Potent neutralizing monoclonal antibodies are one of the few agents currently available to treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the viral spike protein can exhibit neutralization resistance, potentially affecting the effectiveness of some antibody-based therapeutics. Here, the generation of a diverse panel of 91 human, neutralizing monoclonal antibodies provides an in-depth structural and phenotypic definition of receptor binding domain (RBD) antigenic sites on the viral spike. These RBD antibodies ameliorate SARS-CoV-2 infection in mice and hamster models in a dose-dependent manner and in proportion to in vitro, neutralizing potency. Assessing the effect of mutations in the spike protein on antibody recognition and neutralization highlights both potent single antibodies and stereotypic classes of antibodies that are unaffected by currently circulating VOCs, such as B.1.351 and P.1. These neutralizing monoclonal antibodies and others that bind analogous epitopes represent potentially useful future anti-SARS-CoV-2 therapeutics.
リンク	Cell Rep / PubMed:34610292 / PubMed Central
手法	EM (単粒子) / X線回折
解像度	1.85 - 8.3 Å
構造データ	EMDB-24642: SARS-CoV-2 Spike bound to Fab PDI 210 手法: EM (単粒子) / 解像度: 4.2 Å EMDB-24643: SARS-CoV-2 Spike bound to Fab PDI 96 手法: EM (単粒子) / 解像度: 4.2 Å EMDB-24644: SARS-CoV-2 Spike bound to Fab PDI 215 手法: EM (単粒子) / 解像度: 8.3 Å EMDB-24645: SARS-CoV-2 Spike bound to Fab WCSL 119 手法: EM (単粒子) / 解像度: 4.1 Å EMDB-24646: SARS-CoV-2 Spike bound to Fab WCSL 129 手法: EM (単粒子) / 解像度: 4.3 Å EMDB-24647: SARS-CoV-2 Spike bound to Fab PDI 93 手法: EM (単粒子) / 解像度: 4.1 Å EMDB-24648: SARS-CoV-2 Spike bound to Fab PDI 222 手法: EM (単粒子) / 解像度: 4.4 Å 24649 7rr0 EMDB-24649, PDB-7rr0: SARS-CoV-2 receptor binding domain bound to Fab PDI 222 手法: EM (単粒子) / 解像度: 3.12 Å PDB-7mzf: SARS-CoV-2 receptor binding domain bound to Fab PDI 37 手法: X-RAY DIFFRACTION / 解像度: 2.493 Å PDB-7mzg: SARS-CoV-2 receptor binding domain bound to Fab PDI 42 手法: X-RAY DIFFRACTION / 解像度: 2.0 Å PDB-7mzh: SARS-CoV-2 receptor binding domain bound to Fab WCSL 119 手法: X-RAY DIFFRACTION / 解像度: 2.1 Å PDB-7mzi: SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 手法: X-RAY DIFFRACTION / 解像度: 1.85 Å PDB-7mzj: SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 and Fab PDI 93 手法: X-RAY DIFFRACTION / 解像度: 2.4 Å PDB-7mzk: SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 and Fab PDI 96 手法: X-RAY DIFFRACTION / 解像度: 2.25 Å PDB-7mzl: SARS-CoV-2 receptor binding domain bound to Fab PDI 210 手法: X-RAY DIFFRACTION / 解像度: 3.7 Å PDB-7mzm: SARS-CoV-2 receptor binding domain bound to Fab PDI 215 手法: X-RAY DIFFRACTION / 解像度: 2.3 Å PDB-7mzn: SARS-CoV-2 receptor binding domain bound to Fab PDI 231 手法: X-RAY DIFFRACTION / 解像度: 3.1 Å
化合物	ChemComp-SO4: SULFATE ION / 硫酸ジアニオン / 硫酸塩 ChemComp-CL: Unknown entry / クロリド / 塩化物 ChemComp-GOL: GLYCEROL / グリセロ-ル / グリセリン ChemComp-HOH: WATER / 水 ChemComp-PG4: TETRAETHYLENE GLYCOL / テトラエチレングリコ-ル / 沈殿剤YM / ポリエチレングリコール ChemComp-MPD: (4S)-2-METHYL-2,4-PENTANEDIOL / (S)-2-メチル-2,4-ペンタンジオ-ル / 沈殿剤YM / 2-Methyl-2,4-pentanediol ChemComp-CIT: CITRIC ACID / クエン酸 / クエン酸 ChemComp-IPA: ISOPROPYL ALCOHOL / 2-プロパノ-ル / alkaloidYM / 2-プロパノール ChemComp-NAG*: 2-acetamido-2-deoxy-beta-D-glucopyranose / N-アセチル-β-D-グルコサミン / N-アセチルグルコサミン
由来	severe acute respiratory syndrome coronavirus 2 (SARSコロナウイルス2) homo sapiens (ヒト)
キーワード	VIRAL PROTEIN (ウイルスタンパク質) / SARS-CoV-2 (SARSコロナウイルス2) / spike / RBD / human antibody (抗体) / VIRAL PROTEIN/IMMUNE SYSTEM (ウイルス性) / Antibody (抗体) / SARS-CoV-2 RBD / Complex / VIRAL PROTEIN-IMMUNE SYSTEM complex (ウイルス性)